Table 2.

Results of complement analyses after eculizumab (3 × 600 mg within 6 d)^a

Day	APH50 (%)	C3 (mg/ml)	C3d (mU/L)	SC5b-9 (ng/ml)
3	<5	1.04	40	1524
6	nt	0.93	35	1450
9	<5	0.80	43	1348
12	nt	0.77	45	1093
14	nt	0.73	45	1774
16	<5	0.87	37	2149
19	nt	0.78	17	1930
23	39	0.74	55	1676
26	nt	0.69	44	1894
30	47	0.70	46	2207
35	nt	0.87	44	1772
37	124	0.82	48	1809
40	nt	0.90	52	1896
44	nt	0.80	44	1064
47	134	0.69	38	1365

^ant, not tested.